nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—hematologic cancer—muscle cancer	0.698	1	CtDrD
Cladribine—ABCG2—Dactinomycin—muscle cancer	0.0423	0.34	CbGbCtD
Cladribine—ABCG2—Vincristine—muscle cancer	0.0261	0.21	CbGbCtD
Cladribine—ABCG2—Etoposide—muscle cancer	0.0239	0.192	CbGbCtD
Cladribine—ABCG2—Doxorubicin—muscle cancer	0.0163	0.131	CbGbCtD
Cladribine—ABCG2—Methotrexate—muscle cancer	0.0158	0.127	CbGbCtD
Cladribine—RRM1—larynx—muscle cancer	0.00387	0.061	CbGeAlD
Cladribine—POLE4—embryo—muscle cancer	0.00338	0.0533	CbGeAlD
Cladribine—POLE2—embryo—muscle cancer	0.00295	0.0466	CbGeAlD
Cladribine—POLE4—renal system—muscle cancer	0.00256	0.0403	CbGeAlD
Cladribine—POLE2—tendon—muscle cancer	0.00174	0.0275	CbGeAlD
Cladribine—POLE4—head—muscle cancer	0.00171	0.027	CbGeAlD
Cladribine—POLE2—bone marrow—muscle cancer	0.00169	0.0266	CbGeAlD
Cladribine—POLE3—embryo—muscle cancer	0.00164	0.0258	CbGeAlD
Cladribine—POLE2—vagina—muscle cancer	0.00162	0.0255	CbGeAlD
Cladribine—POLE2—testis—muscle cancer	0.00144	0.0228	CbGeAlD
Cladribine—PNP—renal system—muscle cancer	0.00141	0.0223	CbGeAlD
Cladribine—RRM2B—renal system—muscle cancer	0.00131	0.0207	CbGeAlD
Cladribine—RRM1—E2F transcription factor network—TFE3—muscle cancer	0.00126	0.057	CbGpPWpGaD
Cladribine—POLE—embryo—muscle cancer	0.00125	0.0197	CbGeAlD
Cladribine—POLE3—renal system—muscle cancer	0.00124	0.0196	CbGeAlD
Cladribine—RRM2B—cardiac atrium—muscle cancer	0.00118	0.0185	CbGeAlD
Cladribine—POLE3—cardiac atrium—muscle cancer	0.00111	0.0175	CbGeAlD
Cladribine—RRM2B—Direct p53 effectors—PMS2—muscle cancer	0.00109	0.0494	CbGpPWpGaD
Cladribine—PNP—bone marrow—muscle cancer	0.00107	0.0169	CbGeAlD
Cladribine—RRM2—E2F transcription factor network—TFE3—muscle cancer	0.00104	0.047	CbGpPWpGaD
Cladribine—RRM2—embryo—muscle cancer	0.00103	0.0162	CbGeAlD
Cladribine—RRM2B—tendon—muscle cancer	0.00102	0.0162	CbGeAlD
Cladribine—RRM2B—Direct p53 effectors—TP73—muscle cancer	0.00101	0.046	CbGpPWpGaD
Cladribine—RRM2B—bone marrow—muscle cancer	0.000992	0.0156	CbGeAlD
Cladribine—POLE3—tendon—muscle cancer	0.000968	0.0153	CbGeAlD
Cladribine—RRM2B—vagina—muscle cancer	0.00095	0.015	CbGeAlD
Cladribine—PNP—head—muscle cancer	0.000946	0.0149	CbGeAlD
Cladribine—POLE3—bone marrow—muscle cancer	0.000938	0.0148	CbGeAlD
Cladribine—POLE3—vagina—muscle cancer	0.000898	0.0142	CbGeAlD
Cladribine—RRM2B—head—muscle cancer	0.000878	0.0138	CbGeAlD
Cladribine—SLC28A3—bone marrow—muscle cancer	0.000878	0.0138	CbGeAlD
Cladribine—RRM2B—Direct p53 effectors—TP63—muscle cancer	0.000871	0.0395	CbGpPWpGaD
Cladribine—RRM1—E2F transcription factor network—TP73—muscle cancer	0.000849	0.0385	CbGpPWpGaD
Cladribine—RRM2B—testis—muscle cancer	0.000848	0.0134	CbGeAlD
Cladribine—POLE3—head—muscle cancer	0.00083	0.0131	CbGeAlD
Cladribine—NR5A1—head—muscle cancer	0.000804	0.0127	CbGeAlD
Cladribine—POLE3—testis—muscle cancer	0.000802	0.0126	CbGeAlD
Cladribine—POLE2—DNA Repair—PMS2—muscle cancer	0.00079	0.0358	CbGpPWpGaD
Cladribine—RRM2—renal system—muscle cancer	0.000779	0.0123	CbGeAlD
Cladribine—NR5A1—testis—muscle cancer	0.000777	0.0123	CbGeAlD
Cladribine—POLE—tendon—muscle cancer	0.000739	0.0116	CbGeAlD
Cladribine—POLE—bone marrow—muscle cancer	0.000716	0.0113	CbGeAlD
Cladribine—POLA1—E2F transcription factor network—TFE3—muscle cancer	0.000708	0.0321	CbGpPWpGaD
Cladribine—RRM2—E2F transcription factor network—TP73—muscle cancer	0.000699	0.0317	CbGpPWpGaD
Cladribine—POLE—vagina—muscle cancer	0.000685	0.0108	CbGeAlD
Cladribine—POLE2—Teniposide—Etoposide—muscle cancer	0.000675	0.218	CbGdCrCtD
Cladribine—RRM1—smooth muscle tissue—muscle cancer	0.000673	0.0106	CbGeAlD
Cladribine—DCK—embryo—muscle cancer	0.000664	0.0105	CbGeAlD
Cladribine—RRM1—renal system—muscle cancer	0.000647	0.0102	CbGeAlD
Cladribine—POLA1—tendon—muscle cancer	0.000637	0.01	CbGeAlD
Cladribine—POLE—head—muscle cancer	0.000633	0.00998	CbGeAlD
Cladribine—POLA1—bone marrow—muscle cancer	0.000617	0.00972	CbGeAlD
Cladribine—POLE—testis—muscle cancer	0.000612	0.00964	CbGeAlD
Cladribine—RRM2—tendon—muscle cancer	0.000608	0.00959	CbGeAlD
Cladribine—SLC22A2—renal system—muscle cancer	0.000607	0.00957	CbGeAlD
Cladribine—POLA1—vagina—muscle cancer	0.000591	0.00932	CbGeAlD
Cladribine—RRM2—bone marrow—muscle cancer	0.000589	0.00929	CbGeAlD
Cladribine—RRM1—cardiac atrium—muscle cancer	0.00058	0.00914	CbGeAlD
Cladribine—RRM2—vagina—muscle cancer	0.000564	0.0089	CbGeAlD
Cladribine—RRM2—Vinorelbine—Vincristine—muscle cancer	0.000537	0.173	CbGdCrCtD
Cladribine—POLA1—testis—muscle cancer	0.000527	0.00831	CbGeAlD
Cladribine—RRM2—head—muscle cancer	0.000521	0.00822	CbGeAlD
Cladribine—POLE—DNA Repair—PMS2—muscle cancer	0.000509	0.0231	CbGpPWpGaD
Cladribine—POLA1—Vinblastine—Vincristine—muscle cancer	0.000508	0.164	CbGdCrCtD
Cladribine—RRM1—tendon—muscle cancer	0.000505	0.00797	CbGeAlD
Cladribine—RRM2—testis—muscle cancer	0.000504	0.00794	CbGeAlD
Cladribine—RRM1—bone marrow—muscle cancer	0.000489	0.00772	CbGeAlD
Cladribine—NR5A1—Developmental Biology—MYF5—muscle cancer	0.000487	0.0221	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MYF6—muscle cancer	0.000487	0.0221	CbGpPWpGaD
Cladribine—POLA1—E2F transcription factor network—TP73—muscle cancer	0.000478	0.0217	CbGpPWpGaD
Cladribine—RRM1—vagina—muscle cancer	0.000469	0.00739	CbGeAlD
Cladribine—DCK—cardiac atrium—muscle cancer	0.00045	0.0071	CbGeAlD
Cladribine—RRM2B—DNA Damage Response—MDM2—muscle cancer	0.000443	0.0201	CbGpPWpGaD
Cladribine—RRM1—head—muscle cancer	0.000433	0.00683	CbGeAlD
Cladribine—SLC22A1—renal system—muscle cancer	0.000429	0.00676	CbGeAlD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—MDM2—muscle cancer	0.000428	0.0194	CbGpPWpGaD
Cladribine—RRM1—testis—muscle cancer	0.000418	0.0066	CbGeAlD
Cladribine—DCK—tendon—muscle cancer	0.000393	0.00619	CbGeAlD
Cladribine—DCK—bone marrow—muscle cancer	0.00038	0.006	CbGeAlD
Cladribine—DCK—vagina—muscle cancer	0.000364	0.00574	CbGeAlD
Cladribine—DCK—head—muscle cancer	0.000336	0.00531	CbGeAlD
Cladribine—POLE2—Daunorubicin—Doxorubicin—muscle cancer	0.000326	0.105	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Doxorubicin—muscle cancer	0.000326	0.105	CbGdCrCtD
Cladribine—POLE2—Epirubicin—Doxorubicin—muscle cancer	0.000326	0.105	CbGdCrCtD
Cladribine—DCK—testis—muscle cancer	0.000325	0.00512	CbGeAlD
Cladribine—NR5A1—Developmental Biology—MYOG—muscle cancer	0.000314	0.0143	CbGpPWpGaD
Cladribine—SLC22A1—vagina—muscle cancer	0.000311	0.0049	CbGeAlD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000298	0.0135	CbGpPWpGaD
Cladribine—SLC22A1—head—muscle cancer	0.000287	0.00452	CbGeAlD
Cladribine—POLE2—G1 to S cell cycle control—CDKN2A—muscle cancer	0.000279	0.0127	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—MDM2—muscle cancer	0.000271	0.0123	CbGpPWpGaD
Cladribine—RRM2B—DNA Damage Response—TP53—muscle cancer	0.000254	0.0115	CbGpPWpGaD
Cladribine—PNP—Daunorubicin—Doxorubicin—muscle cancer	0.000251	0.0812	CbGdCrCtD
Cladribine—RRM2B—Direct p53 effectors—MDM2—muscle cancer	0.000249	0.0113	CbGpPWpGaD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—TP53—muscle cancer	0.000246	0.0111	CbGpPWpGaD
Cladribine—RRM1—Fluoropyrimidine Activity—TP53—muscle cancer	0.000226	0.0102	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	0.000222	0.0101	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000218	0.00989	CbGpPWpGaD
Cladribine—RRM1—E2F transcription factor network—CDKN2A—muscle cancer	0.000215	0.00976	CbGpPWpGaD
Cladribine—ABCG2—bone marrow—muscle cancer	0.000212	0.00334	CbGeAlD
Cladribine—ABCG2—vagina—muscle cancer	0.000203	0.0032	CbGeAlD
Cladribine—NR5A1—Developmental Biology—MYOD1—muscle cancer	0.000194	0.0088	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—FH—muscle cancer	0.000194	0.0088	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—MED12—muscle cancer	0.000189	0.00856	CbGpPWpGaD
Cladribine—RRM2—Fluoropyrimidine Activity—TP53—muscle cancer	0.000186	0.00844	CbGpPWpGaD
Cladribine—ABCG2—testis—muscle cancer	0.000181	0.00286	CbGeAlD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	0.000181	0.00822	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—CDKN2A—muscle cancer	0.00018	0.00816	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MED12—muscle cancer	0.000177	0.00805	CbGpPWpGaD
Cladribine—RRM2—E2F transcription factor network—CDKN2A—muscle cancer	0.000177	0.00803	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—MDM2—muscle cancer	0.000175	0.00792	CbGpPWpGaD
Cladribine—POLE2—Mitotic M-M/G1 phases—BUB1B—muscle cancer	0.000173	0.00785	CbGpPWpGaD
Cladribine—PNP—Metabolism—FH—muscle cancer	0.000168	0.00763	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000168	0.00762	CbGpPWpGaD
Cladribine—POLE2—Mitotic G1-G1/S phases—CDKN2A—muscle cancer	0.000161	0.00732	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—TP53—muscle cancer	0.000155	0.00705	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	0.000149	0.00677	CbGpPWpGaD
Cladribine—Chills—Etoposide—muscle cancer	0.000149	0.00168	CcSEcCtD
Cladribine—Sepsis—Doxorubicin—muscle cancer	0.000149	0.00168	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000149	0.00167	CcSEcCtD
Cladribine—Alopecia—Etoposide—muscle cancer	0.000147	0.00165	CcSEcCtD
Cladribine—Lethargy—Methotrexate—muscle cancer	0.000147	0.00165	CcSEcCtD
Cladribine—Cerebrovascular accident—Methotrexate—muscle cancer	0.000147	0.00165	CcSEcCtD
Cladribine—DCK—Epirubicin—Doxorubicin—muscle cancer	0.000147	0.0474	CbGdCrCtD
Cladribine—Oedema—Vincristine—muscle cancer	0.000146	0.00164	CcSEcCtD
Cladribine—Infection—Vincristine—muscle cancer	0.000145	0.00163	CcSEcCtD
Cladribine—Phlebitis—Doxorubicin—muscle cancer	0.000145	0.00163	CcSEcCtD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	0.000143	0.0065	CbGpPWpGaD
Cladribine—Nervous system disorder—Vincristine—muscle cancer	0.000143	0.00161	CcSEcCtD
Cladribine—RRM2B—Direct p53 effectors—TP53—muscle cancer	0.000143	0.00648	CbGpPWpGaD
Cladribine—Thrombocytopenia—Vincristine—muscle cancer	0.000143	0.00161	CcSEcCtD
Cladribine—Decreased appetite—Dactinomycin—muscle cancer	0.000142	0.0016	CcSEcCtD
Cladribine—Hyperhidrosis—Vincristine—muscle cancer	0.000141	0.00159	CcSEcCtD
Cladribine—Fatigue—Dactinomycin—muscle cancer	0.000141	0.00158	CcSEcCtD
Cladribine—Back pain—Etoposide—muscle cancer	0.00014	0.00158	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	0.000139	0.00633	CbGpPWpGaD
Cladribine—Pain—Dactinomycin—muscle cancer	0.000139	0.00157	CcSEcCtD
Cladribine—Vascular purpura—Doxorubicin—muscle cancer	0.000139	0.00157	CcSEcCtD
Cladribine—Anorexia—Vincristine—muscle cancer	0.000139	0.00157	CcSEcCtD
Cladribine—Hepatic failure—Doxorubicin—muscle cancer	0.000139	0.00156	CcSEcCtD
Cladribine—Hypotension—Vincristine—muscle cancer	0.000136	0.00153	CcSEcCtD
Cladribine—Ataxia—Methotrexate—muscle cancer	0.000135	0.00152	CcSEcCtD
Cladribine—Renal failure acute—Doxorubicin—muscle cancer	0.000135	0.00152	CcSEcCtD
Cladribine—Feeling abnormal—Dactinomycin—muscle cancer	0.000134	0.00151	CcSEcCtD
Cladribine—Ill-defined disorder—Etoposide—muscle cancer	0.000134	0.00151	CcSEcCtD
Cladribine—Anaemia—Etoposide—muscle cancer	0.000134	0.00151	CcSEcCtD
Cladribine—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000133	0.0015	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000133	0.0015	CcSEcCtD
Cladribine—Insomnia—Vincristine—muscle cancer	0.000132	0.00149	CcSEcCtD
Cladribine—Renal impairment—Doxorubicin—muscle cancer	0.000131	0.00148	CcSEcCtD
Cladribine—Paraesthesia—Vincristine—muscle cancer	0.000131	0.00147	CcSEcCtD
Cladribine—Malaise—Etoposide—muscle cancer	0.00013	0.00147	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.00013	0.00146	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—BUB1B—muscle cancer	0.000129	0.00587	CbGpPWpGaD
Cladribine—Purpura—Doxorubicin—muscle cancer	0.000129	0.00146	CcSEcCtD
Cladribine—Abdominal pain—Dactinomycin—muscle cancer	0.000129	0.00145	CcSEcCtD
Cladribine—Body temperature increased—Dactinomycin—muscle cancer	0.000129	0.00145	CcSEcCtD
Cladribine—Cardiac failure—Doxorubicin—muscle cancer	0.000128	0.00144	CcSEcCtD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	0.000128	0.00579	CbGpPWpGaD
Cladribine—Cerebrovascular accident—Doxorubicin—muscle cancer	0.000127	0.00143	CcSEcCtD
Cladribine—Lethargy—Doxorubicin—muscle cancer	0.000127	0.00143	CcSEcCtD
Cladribine—Decreased appetite—Vincristine—muscle cancer	0.000127	0.00143	CcSEcCtD
Cladribine—Cough—Etoposide—muscle cancer	0.000126	0.00142	CcSEcCtD
Cladribine—Gastrointestinal disorder—Vincristine—muscle cancer	0.000126	0.00142	CcSEcCtD
Cladribine—Fatigue—Vincristine—muscle cancer	0.000126	0.00142	CcSEcCtD
Cladribine—Constipation—Vincristine—muscle cancer	0.000125	0.0014	CcSEcCtD
Cladribine—Pain—Vincristine—muscle cancer	0.000125	0.0014	CcSEcCtD
Cladribine—Pain in extremity—Doxorubicin—muscle cancer	0.000125	0.0014	CcSEcCtD
Cladribine—Chest pain—Etoposide—muscle cancer	0.000123	0.00139	CcSEcCtD
Cladribine—Eosinophilia—Methotrexate—muscle cancer	0.000123	0.00139	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000123	0.00557	CbGpPWpGaD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000122	0.00138	CcSEcCtD
Cladribine—Discomfort—Etoposide—muscle cancer	0.000122	0.00137	CcSEcCtD
Cladribine—POLA1—E2F transcription factor network—CDKN2A—muscle cancer	0.000121	0.0055	CbGpPWpGaD
Cladribine—Hypersensitivity—Dactinomycin—muscle cancer	0.00012	0.00135	CcSEcCtD
Cladribine—Abdominal discomfort—Methotrexate—muscle cancer	0.000119	0.00134	CcSEcCtD
Cladribine—Gastrointestinal pain—Vincristine—muscle cancer	0.000119	0.00134	CcSEcCtD
Cladribine—Confusional state—Etoposide—muscle cancer	0.000119	0.00134	CcSEcCtD
Cladribine—Pancytopenia—Methotrexate—muscle cancer	0.000118	0.00133	CcSEcCtD
Cladribine—Infection—Etoposide—muscle cancer	0.000117	0.00132	CcSEcCtD
Cladribine—Ataxia—Doxorubicin—muscle cancer	0.000117	0.00132	CcSEcCtD
Cladribine—Asthenia—Dactinomycin—muscle cancer	0.000117	0.00132	CcSEcCtD
Cladribine—Neutropenia—Methotrexate—muscle cancer	0.000116	0.00131	CcSEcCtD
Cladribine—POLE2—Cell Cycle—BUB1B—muscle cancer	0.000116	0.00525	CbGpPWpGaD
Cladribine—Thrombocytopenia—Etoposide—muscle cancer	0.000116	0.0013	CcSEcCtD
Cladribine—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000116	0.0013	CcSEcCtD
Cladribine—Tachycardia—Etoposide—muscle cancer	0.000115	0.0013	CcSEcCtD
Cladribine—Body temperature increased—Vincristine—muscle cancer	0.000115	0.0013	CcSEcCtD
Cladribine—Abdominal pain—Vincristine—muscle cancer	0.000115	0.0013	CcSEcCtD
Cladribine—Skin disorder—Etoposide—muscle cancer	0.000115	0.00129	CcSEcCtD
Cladribine—Hyperhidrosis—Etoposide—muscle cancer	0.000114	0.00129	CcSEcCtD
Cladribine—Anorexia—Etoposide—muscle cancer	0.000113	0.00127	CcSEcCtD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.000112	0.00509	CbGpPWpGaD
Cladribine—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000112	0.00126	CcSEcCtD
Cladribine—Diarrhoea—Dactinomycin—muscle cancer	0.000112	0.00126	CcSEcCtD
Cladribine—POLE—Mitotic M-M/G1 phases—BUB1B—muscle cancer	0.000112	0.00506	CbGpPWpGaD
Cladribine—Pneumonia—Methotrexate—muscle cancer	0.000111	0.00126	CcSEcCtD
Cladribine—Infestation NOS—Methotrexate—muscle cancer	0.000111	0.00125	CcSEcCtD
Cladribine—Infestation—Methotrexate—muscle cancer	0.000111	0.00125	CcSEcCtD
Cladribine—Hypotension—Etoposide—muscle cancer	0.00011	0.00124	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.00011	0.00124	CcSEcCtD
Cladribine—Muscular weakness—Doxorubicin—muscle cancer	0.00011	0.00124	CcSEcCtD
Cladribine—RRM2B—Metabolism—MED12—muscle cancer	0.00011	0.00497	CbGpPWpGaD
Cladribine—Renal failure—Methotrexate—muscle cancer	0.000109	0.00123	CcSEcCtD
Cladribine—RRM2—Mitotic G1-G1/S phases—CDKN2A—muscle cancer	0.000108	0.00491	CbGpPWpGaD
Cladribine—Conjunctivitis—Methotrexate—muscle cancer	0.000108	0.00121	CcSEcCtD
Cladribine—Hypersensitivity—Vincristine—muscle cancer	0.000107	0.00121	CcSEcCtD
Cladribine—Eosinophilia—Doxorubicin—muscle cancer	0.000107	0.0012	CcSEcCtD
Cladribine—Paraesthesia—Etoposide—muscle cancer	0.000106	0.00119	CcSEcCtD
Cladribine—Dyspnoea—Etoposide—muscle cancer	0.000105	0.00119	CcSEcCtD
Cladribine—Somnolence—Etoposide—muscle cancer	0.000105	0.00118	CcSEcCtD
Cladribine—Hepatobiliary disease—Methotrexate—muscle cancer	0.000105	0.00118	CcSEcCtD
Cladribine—Epistaxis—Methotrexate—muscle cancer	0.000105	0.00118	CcSEcCtD
Cladribine—Asthenia—Vincristine—muscle cancer	0.000105	0.00118	CcSEcCtD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	0.000104	0.00472	CbGpPWpGaD
Cladribine—POLE—Mitotic G1-G1/S phases—CDKN2A—muscle cancer	0.000104	0.00472	CbGpPWpGaD
Cladribine—Vomiting—Dactinomycin—muscle cancer	0.000104	0.00117	CcSEcCtD
Cladribine—Rash—Dactinomycin—muscle cancer	0.000103	0.00116	CcSEcCtD
Cladribine—Decreased appetite—Etoposide—muscle cancer	0.000103	0.00116	CcSEcCtD
Cladribine—Pancytopenia—Doxorubicin—muscle cancer	0.000102	0.00115	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	0.000102	0.00463	CbGpPWpGaD
Cladribine—Gastrointestinal disorder—Etoposide—muscle cancer	0.000102	0.00115	CcSEcCtD
Cladribine—Fatigue—Etoposide—muscle cancer	0.000102	0.00115	CcSEcCtD
Cladribine—Constipation—Etoposide—muscle cancer	0.000101	0.00114	CcSEcCtD
Cladribine—Pain—Etoposide—muscle cancer	0.000101	0.00114	CcSEcCtD
Cladribine—Neutropenia—Doxorubicin—muscle cancer	0.000101	0.00113	CcSEcCtD
Cladribine—POLE—G1 to S cell cycle control—TP53—muscle cancer	0.0001	0.00454	CbGpPWpGaD
Cladribine—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.0001	0.00113	CcSEcCtD
Cladribine—Haemoglobin—Methotrexate—muscle cancer	0.0001	0.00113	CcSEcCtD
Cladribine—RRM2B—Metabolism—ENO2—muscle cancer	9.99e-05	0.00453	CbGpPWpGaD
Cladribine—Diarrhoea—Vincristine—muscle cancer	9.97e-05	0.00112	CcSEcCtD
Cladribine—Haemorrhage—Methotrexate—muscle cancer	9.95e-05	0.00112	CcSEcCtD
Cladribine—Pharyngitis—Methotrexate—muscle cancer	9.88e-05	0.00111	CcSEcCtD
Cladribine—Urinary tract disorder—Methotrexate—muscle cancer	9.83e-05	0.00111	CcSEcCtD
Cladribine—Urethral disorder—Methotrexate—muscle cancer	9.76e-05	0.0011	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—FOXO1—muscle cancer	9.74e-05	0.00442	CbGpPWpGaD
Cladribine—Feeling abnormal—Etoposide—muscle cancer	9.73e-05	0.0011	CcSEcCtD
Cladribine—Nausea—Dactinomycin—muscle cancer	9.69e-05	0.00109	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	9.66e-05	0.00438	CbGpPWpGaD
Cladribine—RRM1—Metabolism—FH—muscle cancer	9.66e-05	0.00438	CbGpPWpGaD
Cladribine—Pneumonia—Doxorubicin—muscle cancer	9.65e-05	0.00109	CcSEcCtD
Cladribine—Gastrointestinal pain—Etoposide—muscle cancer	9.65e-05	0.00109	CcSEcCtD
Cladribine—Dizziness—Vincristine—muscle cancer	9.64e-05	0.00109	CcSEcCtD
Cladribine—Infestation NOS—Doxorubicin—muscle cancer	9.6e-05	0.00108	CcSEcCtD
Cladribine—Infestation—Doxorubicin—muscle cancer	9.6e-05	0.00108	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	9.52e-05	0.00107	CcSEcCtD
Cladribine—PNP—Metabolism—MED12—muscle cancer	9.5e-05	0.00431	CbGpPWpGaD
Cladribine—Renal failure—Doxorubicin—muscle cancer	9.44e-05	0.00106	CcSEcCtD
Cladribine—Erythema multiforme—Methotrexate—muscle cancer	9.41e-05	0.00106	CcSEcCtD
Cladribine—Urticaria—Etoposide—muscle cancer	9.38e-05	0.00106	CcSEcCtD
Cladribine—Abdominal pain—Etoposide—muscle cancer	9.33e-05	0.00105	CcSEcCtD
Cladribine—Body temperature increased—Etoposide—muscle cancer	9.33e-05	0.00105	CcSEcCtD
Cladribine—Conjunctivitis—Doxorubicin—muscle cancer	9.33e-05	0.00105	CcSEcCtD
Cladribine—Urinary tract infection—Doxorubicin—muscle cancer	9.33e-05	0.00105	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	9.32e-05	0.00423	CbGpPWpGaD
Cladribine—Eye disorder—Methotrexate—muscle cancer	9.3e-05	0.00105	CcSEcCtD
Cladribine—Vomiting—Vincristine—muscle cancer	9.26e-05	0.00104	CcSEcCtD
Cladribine—Cardiac disorder—Methotrexate—muscle cancer	9.24e-05	0.00104	CcSEcCtD
Cladribine—Rash—Vincristine—muscle cancer	9.19e-05	0.00104	CcSEcCtD
Cladribine—Dermatitis—Vincristine—muscle cancer	9.18e-05	0.00103	CcSEcCtD
Cladribine—Headache—Vincristine—muscle cancer	9.13e-05	0.00103	CcSEcCtD
Cladribine—NR5A1—Gene Expression—MED12—muscle cancer	9.08e-05	0.00412	CbGpPWpGaD
Cladribine—Hepatobiliary disease—Doxorubicin—muscle cancer	9.08e-05	0.00102	CcSEcCtD
Cladribine—Epistaxis—Doxorubicin—muscle cancer	9.05e-05	0.00102	CcSEcCtD
Cladribine—Angiopathy—Methotrexate—muscle cancer	9.03e-05	0.00102	CcSEcCtD
Cladribine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	8.99e-05	0.00408	CbGpPWpGaD
Cladribine—Immune system disorder—Methotrexate—muscle cancer	8.99e-05	0.00101	CcSEcCtD
Cladribine—Mediastinal disorder—Methotrexate—muscle cancer	8.97e-05	0.00101	CcSEcCtD
Cladribine—Chills—Methotrexate—muscle cancer	8.93e-05	0.00101	CcSEcCtD
Cladribine—Alopecia—Methotrexate—muscle cancer	8.79e-05	0.000991	CcSEcCtD
Cladribine—Mental disorder—Methotrexate—muscle cancer	8.72e-05	0.000983	CcSEcCtD
Cladribine—Hypersensitivity—Etoposide—muscle cancer	8.7e-05	0.00098	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—BUB1B—muscle cancer	8.69e-05	0.00394	CbGpPWpGaD
Cladribine—Malnutrition—Methotrexate—muscle cancer	8.66e-05	0.000976	CcSEcCtD
Cladribine—Erythema—Methotrexate—muscle cancer	8.66e-05	0.000976	CcSEcCtD
Cladribine—Haemoglobin—Doxorubicin—muscle cancer	8.66e-05	0.000976	CcSEcCtD
Cladribine—PNP—Metabolism—ENO2—muscle cancer	8.66e-05	0.00393	CbGpPWpGaD
Cladribine—Nausea—Vincristine—muscle cancer	8.66e-05	0.000975	CcSEcCtD
Cladribine—Haemorrhage—Doxorubicin—muscle cancer	8.62e-05	0.000971	CcSEcCtD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	8.56e-05	0.00389	CbGpPWpGaD
Cladribine—Pharyngitis—Doxorubicin—muscle cancer	8.55e-05	0.000964	CcSEcCtD
Cladribine—Urinary tract disorder—Doxorubicin—muscle cancer	8.51e-05	0.000959	CcSEcCtD
Cladribine—Oedema peripheral—Doxorubicin—muscle cancer	8.49e-05	0.000957	CcSEcCtD
Cladribine—Asthenia—Etoposide—muscle cancer	8.47e-05	0.000955	CcSEcCtD
Cladribine—Connective tissue disorder—Doxorubicin—muscle cancer	8.47e-05	0.000954	CcSEcCtD
Cladribine—Urethral disorder—Doxorubicin—muscle cancer	8.45e-05	0.000952	CcSEcCtD
Cladribine—Back pain—Methotrexate—muscle cancer	8.38e-05	0.000944	CcSEcCtD
Cladribine—Pruritus—Etoposide—muscle cancer	8.35e-05	0.000941	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—BUB1B—muscle cancer	8.34e-05	0.00379	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	8.22e-05	0.00373	CbGpPWpGaD
Cladribine—Erythema multiforme—Doxorubicin—muscle cancer	8.15e-05	0.000918	CcSEcCtD
Cladribine—Diarrhoea—Etoposide—muscle cancer	8.08e-05	0.00091	CcSEcCtD
Cladribine—Eye disorder—Doxorubicin—muscle cancer	8.05e-05	0.000908	CcSEcCtD
Cladribine—Ill-defined disorder—Methotrexate—muscle cancer	8.04e-05	0.000906	CcSEcCtD
Cladribine—Anaemia—Methotrexate—muscle cancer	8.01e-05	0.000902	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	8e-05	0.00363	CbGpPWpGaD
Cladribine—Cardiac disorder—Doxorubicin—muscle cancer	8e-05	0.000901	CcSEcCtD
Cladribine—RRM2—Metabolism—FH—muscle cancer	7.95e-05	0.00361	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—BUB1B—muscle cancer	7.95e-05	0.00361	CbGpPWpGaD
Cladribine—Angiopathy—Doxorubicin—muscle cancer	7.82e-05	0.000881	CcSEcCtD
Cladribine—Malaise—Methotrexate—muscle cancer	7.81e-05	0.000881	CcSEcCtD
Cladribine—Dizziness—Etoposide—muscle cancer	7.81e-05	0.00088	CcSEcCtD
Cladribine—Immune system disorder—Doxorubicin—muscle cancer	7.78e-05	0.000877	CcSEcCtD
Cladribine—RRM2—Cell Cycle—BUB1B—muscle cancer	7.77e-05	0.00353	CbGpPWpGaD
Cladribine—Mediastinal disorder—Doxorubicin—muscle cancer	7.77e-05	0.000875	CcSEcCtD
Cladribine—Chills—Doxorubicin—muscle cancer	7.73e-05	0.000871	CcSEcCtD
Cladribine—Arrhythmia—Doxorubicin—muscle cancer	7.7e-05	0.000868	CcSEcCtD
Cladribine—Alopecia—Doxorubicin—muscle cancer	7.61e-05	0.000858	CcSEcCtD
Cladribine—Cough—Methotrexate—muscle cancer	7.56e-05	0.000852	CcSEcCtD
Cladribine—Mental disorder—Doxorubicin—muscle cancer	7.55e-05	0.000851	CcSEcCtD
Cladribine—Vomiting—Etoposide—muscle cancer	7.5e-05	0.000846	CcSEcCtD
Cladribine—Erythema—Doxorubicin—muscle cancer	7.5e-05	0.000845	CcSEcCtD
Cladribine—Malnutrition—Doxorubicin—muscle cancer	7.5e-05	0.000845	CcSEcCtD
Cladribine—POLE—Cell Cycle—BUB1B—muscle cancer	7.46e-05	0.00338	CbGpPWpGaD
Cladribine—Rash—Etoposide—muscle cancer	7.44e-05	0.000839	CcSEcCtD
Cladribine—Dermatitis—Etoposide—muscle cancer	7.44e-05	0.000838	CcSEcCtD
Cladribine—DCK—Metabolism—FH—muscle cancer	7.43e-05	0.00337	CbGpPWpGaD
Cladribine—POLA1—Mitotic G1-G1/S phases—CDKN2A—muscle cancer	7.41e-05	0.00336	CbGpPWpGaD
Cladribine—Headache—Etoposide—muscle cancer	7.39e-05	0.000833	CcSEcCtD
Cladribine—Flatulence—Doxorubicin—muscle cancer	7.39e-05	0.000833	CcSEcCtD
Cladribine—Myalgia—Methotrexate—muscle cancer	7.38e-05	0.000831	CcSEcCtD
Cladribine—Chest pain—Methotrexate—muscle cancer	7.38e-05	0.000831	CcSEcCtD
Cladribine—Arthralgia—Methotrexate—muscle cancer	7.38e-05	0.000831	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	7.34e-05	0.00333	CbGpPWpGaD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	7.32e-05	0.000826	CcSEcCtD
Cladribine—Discomfort—Methotrexate—muscle cancer	7.29e-05	0.000821	CcSEcCtD
Cladribine—Back pain—Doxorubicin—muscle cancer	7.26e-05	0.000818	CcSEcCtD
Cladribine—Confusional state—Methotrexate—muscle cancer	7.13e-05	0.000803	CcSEcCtD
Cladribine—Infection—Methotrexate—muscle cancer	7.02e-05	0.000792	CcSEcCtD
Cladribine—Nausea—Etoposide—muscle cancer	7.01e-05	0.00079	CcSEcCtD
Cladribine—Ill-defined disorder—Doxorubicin—muscle cancer	6.96e-05	0.000784	CcSEcCtD
Cladribine—ABCG2—Fluoropyrimidine Activity—TP53—muscle cancer	6.96e-05	0.00316	CbGpPWpGaD
Cladribine—Nervous system disorder—Methotrexate—muscle cancer	6.93e-05	0.000781	CcSEcCtD
Cladribine—Anaemia—Doxorubicin—muscle cancer	6.93e-05	0.000781	CcSEcCtD
Cladribine—Thrombocytopenia—Methotrexate—muscle cancer	6.92e-05	0.00078	CcSEcCtD
Cladribine—Skin disorder—Methotrexate—muscle cancer	6.87e-05	0.000774	CcSEcCtD
Cladribine—Hyperhidrosis—Methotrexate—muscle cancer	6.83e-05	0.00077	CcSEcCtD
Cladribine—Malaise—Doxorubicin—muscle cancer	6.76e-05	0.000762	CcSEcCtD
Cladribine—Anorexia—Methotrexate—muscle cancer	6.74e-05	0.00076	CcSEcCtD
Cladribine—Hypotension—Methotrexate—muscle cancer	6.61e-05	0.000745	CcSEcCtD
Cladribine—Cough—Doxorubicin—muscle cancer	6.55e-05	0.000738	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Methotrexate—muscle cancer	6.44e-05	0.000726	CcSEcCtD
Cladribine—Insomnia—Methotrexate—muscle cancer	6.39e-05	0.000721	CcSEcCtD
Cladribine—Arthralgia—Doxorubicin—muscle cancer	6.39e-05	0.00072	CcSEcCtD
Cladribine—Chest pain—Doxorubicin—muscle cancer	6.39e-05	0.00072	CcSEcCtD
Cladribine—Myalgia—Doxorubicin—muscle cancer	6.39e-05	0.00072	CcSEcCtD
Cladribine—Anxiety—Doxorubicin—muscle cancer	6.36e-05	0.000717	CcSEcCtD
Cladribine—Paraesthesia—Methotrexate—muscle cancer	6.35e-05	0.000716	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	6.34e-05	0.000715	CcSEcCtD
Cladribine—Discomfort—Doxorubicin—muscle cancer	6.31e-05	0.000711	CcSEcCtD
Cladribine—Dyspnoea—Methotrexate—muscle cancer	6.3e-05	0.00071	CcSEcCtD
Cladribine—Somnolence—Methotrexate—muscle cancer	6.29e-05	0.000708	CcSEcCtD
Cladribine—Confusional state—Doxorubicin—muscle cancer	6.17e-05	0.000696	CcSEcCtD
Cladribine—Decreased appetite—Methotrexate—muscle cancer	6.15e-05	0.000693	CcSEcCtD
Cladribine—Oedema—Doxorubicin—muscle cancer	6.12e-05	0.00069	CcSEcCtD
Cladribine—Gastrointestinal disorder—Methotrexate—muscle cancer	6.1e-05	0.000688	CcSEcCtD
Cladribine—Fatigue—Methotrexate—muscle cancer	6.1e-05	0.000687	CcSEcCtD
Cladribine—Infection—Doxorubicin—muscle cancer	6.08e-05	0.000686	CcSEcCtD
Cladribine—Pain—Methotrexate—muscle cancer	6.05e-05	0.000681	CcSEcCtD
Cladribine—Nervous system disorder—Doxorubicin—muscle cancer	6e-05	0.000677	CcSEcCtD
Cladribine—Thrombocytopenia—Doxorubicin—muscle cancer	5.99e-05	0.000676	CcSEcCtD
Cladribine—Tachycardia—Doxorubicin—muscle cancer	5.97e-05	0.000673	CcSEcCtD
Cladribine—Skin disorder—Doxorubicin—muscle cancer	5.95e-05	0.00067	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—BUB1B—muscle cancer	5.95e-05	0.0027	CbGpPWpGaD
Cladribine—Hyperhidrosis—Doxorubicin—muscle cancer	5.92e-05	0.000667	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—CDKN2A—muscle cancer	5.92e-05	0.00268	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	5.86e-05	0.00266	CbGpPWpGaD
Cladribine—Anorexia—Doxorubicin—muscle cancer	5.84e-05	0.000658	CcSEcCtD
Cladribine—Feeling abnormal—Methotrexate—muscle cancer	5.83e-05	0.000657	CcSEcCtD
Cladribine—Gastrointestinal pain—Methotrexate—muscle cancer	5.78e-05	0.000652	CcSEcCtD
Cladribine—Hypotension—Doxorubicin—muscle cancer	5.72e-05	0.000645	CcSEcCtD
Cladribine—Urticaria—Methotrexate—muscle cancer	5.62e-05	0.000633	CcSEcCtD
Cladribine—Abdominal pain—Methotrexate—muscle cancer	5.59e-05	0.00063	CcSEcCtD
Cladribine—Body temperature increased—Methotrexate—muscle cancer	5.59e-05	0.00063	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	5.58e-05	0.000629	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	5.54e-05	0.00252	CbGpPWpGaD
Cladribine—Insomnia—Doxorubicin—muscle cancer	5.54e-05	0.000624	CcSEcCtD
Cladribine—Paraesthesia—Doxorubicin—muscle cancer	5.5e-05	0.00062	CcSEcCtD
Cladribine—Dyspnoea—Doxorubicin—muscle cancer	5.46e-05	0.000615	CcSEcCtD
Cladribine—RRM1—Metabolism—MED12—muscle cancer	5.46e-05	0.00248	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	5.44e-05	0.00247	CbGpPWpGaD
Cladribine—Somnolence—Doxorubicin—muscle cancer	5.44e-05	0.000613	CcSEcCtD
Cladribine—Decreased appetite—Doxorubicin—muscle cancer	5.32e-05	0.0006	CcSEcCtD
Cladribine—POLA1—Cell Cycle—BUB1B—muscle cancer	5.32e-05	0.00241	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—CDKN2A—muscle cancer	5.29e-05	0.0024	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	5.29e-05	0.0024	CbGpPWpGaD
Cladribine—Gastrointestinal disorder—Doxorubicin—muscle cancer	5.29e-05	0.000596	CcSEcCtD
Cladribine—Fatigue—Doxorubicin—muscle cancer	5.28e-05	0.000595	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	5.25e-05	0.00238	CbGpPWpGaD
Cladribine—Constipation—Doxorubicin—muscle cancer	5.24e-05	0.00059	CcSEcCtD
Cladribine—Pain—Doxorubicin—muscle cancer	5.24e-05	0.00059	CcSEcCtD
Cladribine—Hypersensitivity—Methotrexate—muscle cancer	5.21e-05	0.000587	CcSEcCtD
Cladribine—POLE2—Cell Cycle—MDM2—muscle cancer	5.13e-05	0.00233	CbGpPWpGaD
Cladribine—Asthenia—Methotrexate—muscle cancer	5.07e-05	0.000572	CcSEcCtD
Cladribine—Feeling abnormal—Doxorubicin—muscle cancer	5.04e-05	0.000569	CcSEcCtD
Cladribine—Gastrointestinal pain—Doxorubicin—muscle cancer	5.01e-05	0.000564	CcSEcCtD
Cladribine—Pruritus—Methotrexate—muscle cancer	5e-05	0.000564	CcSEcCtD
Cladribine—RRM1—Metabolism—ENO2—muscle cancer	4.97e-05	0.00226	CbGpPWpGaD
Cladribine—Urticaria—Doxorubicin—muscle cancer	4.86e-05	0.000548	CcSEcCtD
Cladribine—Body temperature increased—Doxorubicin—muscle cancer	4.84e-05	0.000545	CcSEcCtD
Cladribine—Abdominal pain—Doxorubicin—muscle cancer	4.84e-05	0.000545	CcSEcCtD
Cladribine—Diarrhoea—Methotrexate—muscle cancer	4.84e-05	0.000545	CcSEcCtD
Cladribine—Dizziness—Methotrexate—muscle cancer	4.68e-05	0.000527	CcSEcCtD
Cladribine—Hypersensitivity—Doxorubicin—muscle cancer	4.51e-05	0.000508	CcSEcCtD
Cladribine—Vomiting—Methotrexate—muscle cancer	4.5e-05	0.000507	CcSEcCtD
Cladribine—RRM2—Metabolism—MED12—muscle cancer	4.49e-05	0.00204	CbGpPWpGaD
Cladribine—Rash—Methotrexate—muscle cancer	4.46e-05	0.000502	CcSEcCtD
Cladribine—Dermatitis—Methotrexate—muscle cancer	4.45e-05	0.000502	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—VEGFA—muscle cancer	4.44e-05	0.00201	CbGpPWpGaD
Cladribine—Headache—Methotrexate—muscle cancer	4.43e-05	0.000499	CcSEcCtD
Cladribine—Asthenia—Doxorubicin—muscle cancer	4.39e-05	0.000495	CcSEcCtD
Cladribine—Pruritus—Doxorubicin—muscle cancer	4.33e-05	0.000488	CcSEcCtD
Cladribine—Nausea—Methotrexate—muscle cancer	4.2e-05	0.000473	CcSEcCtD
Cladribine—DCK—Metabolism—MED12—muscle cancer	4.2e-05	0.0019	CbGpPWpGaD
Cladribine—Diarrhoea—Doxorubicin—muscle cancer	4.19e-05	0.000472	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	4.13e-05	0.00188	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ENO2—muscle cancer	4.1e-05	0.00186	CbGpPWpGaD
Cladribine—Dizziness—Doxorubicin—muscle cancer	4.05e-05	0.000456	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—CDKN2A—muscle cancer	3.97e-05	0.0018	CbGpPWpGaD
Cladribine—Vomiting—Doxorubicin—muscle cancer	3.89e-05	0.000439	CcSEcCtD
Cladribine—Rash—Doxorubicin—muscle cancer	3.86e-05	0.000435	CcSEcCtD
Cladribine—Dermatitis—Doxorubicin—muscle cancer	3.86e-05	0.000435	CcSEcCtD
Cladribine—Headache—Doxorubicin—muscle cancer	3.84e-05	0.000432	CcSEcCtD
Cladribine—DCK—Metabolism—ENO2—muscle cancer	3.83e-05	0.00174	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CDKN2A—muscle cancer	3.81e-05	0.00173	CbGpPWpGaD
Cladribine—Nausea—Doxorubicin—muscle cancer	3.64e-05	0.00041	CcSEcCtD
Cladribine—RRM2—Cell Cycle—CDKN2A—muscle cancer	3.55e-05	0.00161	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTGS2—muscle cancer	3.48e-05	0.00158	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MDM2—muscle cancer	3.44e-05	0.00156	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CDKN2A—muscle cancer	3.41e-05	0.00155	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MDM2—muscle cancer	3.31e-05	0.0015	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.12e-05	0.00142	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTGS2—muscle cancer	3.02e-05	0.00137	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—FH—muscle cancer	2.97e-05	0.00135	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—muscle cancer	2.94e-05	0.00134	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—FH—muscle cancer	2.94e-05	0.00134	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—MDM2—muscle cancer	2.84e-05	0.00129	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—FH—muscle cancer	2.74e-05	0.00124	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDKN2A—muscle cancer	2.72e-05	0.00123	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—MDM2—muscle cancer	2.65e-05	0.0012	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN2A—muscle cancer	2.43e-05	0.0011	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MDM2—muscle cancer	2.36e-05	0.00107	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—MDM2—muscle cancer	2.17e-05	0.000987	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—MDM2—muscle cancer	2.03e-05	0.00092	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—muscle cancer	1.98e-05	0.000897	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—muscle cancer	1.9e-05	0.000861	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS2—muscle cancer	1.73e-05	0.000786	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—MED12—muscle cancer	1.68e-05	0.000762	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—MED12—muscle cancer	1.66e-05	0.000754	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—MED12—muscle cancer	1.55e-05	0.000703	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ENO2—muscle cancer	1.53e-05	0.000695	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ENO2—muscle cancer	1.52e-05	0.000688	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS2—muscle cancer	1.43e-05	0.000647	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ENO2—muscle cancer	1.41e-05	0.000641	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—muscle cancer	1.35e-05	0.000613	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS2—muscle cancer	1.33e-05	0.000605	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS2—muscle cancer	5.34e-06	0.000242	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS2—muscle cancer	5.28e-06	0.00024	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS2—muscle cancer	4.92e-06	0.000223	CbGpPWpGaD
